Kyverna Therapeutics, Inc. - 10-Q Filing
Kyverna Therapeutics reports Q3 financial results including research and development expenses, license agreements with Kite Pharma and Intellia Therapeutics, and updates to loan and security facilities.
Tickers: $KYTX